DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 205065
» See Plans and Pricing
NDA 205065 describes KUVAN, which is a drug marketed by Biomarin Pharm and is included in two NDAs. There are eleven patents protecting this drug and three Paragraph IV challenges. Additional details are available on the KUVAN profile page.
The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this compound. Additional details are available on the sapropterin dihydrochloride profile page.
The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this compound. Additional details are available on the sapropterin dihydrochloride profile page.
Summary for 205065
| Tradename: | KUVAN |
| Applicant: | Biomarin Pharm |
| Ingredient: | sapropterin dihydrochloride |
| Patents: | 6 |
Paragraph IV (Patent) Challenges for 205065
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| KUVAN | POWDER;ORAL | sapropterin dihydrochloride | 205065 | 2017-02-23 |
| KUVAN | POWDER;ORAL | sapropterin dihydrochloride | 205065 | 2015-11-09 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;ORAL | Strength | 100MG/PACKET | ||||
| Approval Date: | Dec 19, 2013 | TE: | AB | RLD: | Yes | ||||
| Patent: | Start Trial | Patent Expiration: | May 17, 2025 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
| Patent: | Start Trial | Patent Expiration: | May 17, 2025 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
| Patent: | Start Trial | Patent Expiration: | May 17, 2025 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Complete Access Available with Subscription
